“We are happy to welcome
“I am pleased to be joining Barinthus Bio at this phase in the company’s trajectory,” said
About Barinthus Biotherapeutics
Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP; Barinthus Bio is advancing a pipeline of four product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk HPV infection; VTP-1000, an autoimmune candidate designed to utilize the SNAP-Tolerance Immunotherapy (TI) platform to treat patients with celiac disease; and VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Bio’s proven scientific expertise, diverse portfolio, and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity, and cancers that have a significant impact on their everyday lives. For more information, visit www.barinthusbio.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “may,” “will,” “plan,” “forward,” “encouraging,” “believe,” “potential,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding our product development activities and clinical trials, including timing for readouts of any interim data or next steps for any of our programs, our ability to develop and advance our current and future product candidates and programs, and our expectation that Dr. Hooftman’s experience as a clinician and biotech CMO will be invaluable to the advancement of our extensive pipeline. Any forward-looking statements in this press release are based on our management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of our pipeline development activities and planned and ongoing clinical trials, our ability to execute on our strategy, regulatory developments, our ability to fund our operations and access capital, that Dr. Hooftman’s prior experience and appointment as our CMO may not be predictive of Barinthus Bio’s advancement of its product candidates; that Dr. Hooftman’s expertise and guidance may not necessarily be predictive of Barinthus Bio’s success in advancement of its pipeline, the risk that interim or topline data may not reflect final data or results, global economic uncertainty, including disruptions in the banking industry, the conflict in
IR contacts:
Christopher M. Calabrese
Managing Director
+1 917-680-5608
ccalabrese@lifesciadvisors.com
Managing Director
+1 617-283-2856
kgardner@lifesciadvisors.com
Media contact:
+1 917-519-9577
audrafriis@sambrown.com
Company contact:
IR & PR Manager
Barinthus Bio
IR@barinthusbio.com
Source: Barinthus Biotherapeutics
2024 GlobeNewswire, Inc., source